Multiple Myeloma

Adding isatuximab to carfilzomib and dexamethasone improved progression-free survival in patients with relapsed multiple myeloma, meeting the primary end point of the phase 3 IKEMA trial.

Larry Anderson, MD, PhD, discusses recent advances made with novel therapies in multiple myeloma.

Nina Shah, MD and Sandy Wong, MD, discuss the predictive value of minimal residual disease and the need for treatment in a patient with smoldering multiple myeloma.

Marc J. Braunstein, MD, PhD, discusses quadruplet therapies in multiple myeloma.

Andrew Yee, MD, discusses the role of carfilzomib in relapsed/refractory multiple myeloma.

A European panel has recommended approval of a subcutaneous formulation of daratumumab for the treatment of patients with multiple myeloma.

A new drug application has been submitted in Japan seeking approval of a subcutaneous formulation of daratumumab.

Noopur Raje, MD, discusses future research with bispecific T-cell engagers in multiple myeloma.

Noopur Raje, MD, discusses the potential utility of belantamab mafodotin in multiple myeloma.

Nina Shah, MD, associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the role of venetoclax (Venclexta) in multiple myeloma.

Nina Shah, MD, highlights some of the recent advances that have been made with CAR T-cell therapy in multiple myeloma, as well as other exciting updates in the space.

Robb S. Friedman, MD, discusses the future of selinexor in multiple myeloma.

Andrew Yee, MD, discusses treatment considerations in relapsed/refractory multiple myeloma.

James Weitzman, MD, discusses the challenges of treating patients with penta-refractory multiple myeloma.

The 3-drug induction regimen of lenalidomide, bortezomib, and dexamethasone led to impressive overall survival outcomes and a very good partial response or better in nearly 90% of patients with newly diagnosed multiple myeloma.

Gareth J. Morgan, MD, PhD, discusses research examining idecabtagene vicleucel in relapsed/refractory multiple myeloma.

Marc J. Braunstein, MD, PhD, factors to consider when determining whether a patient with multiple myeloma is eligible for stem cell transplant.

Shaji Kumar, MD, discusses the role of stem cell transplant in multiple myeloma, different techniques for stem cell mobilization, and remaining challenges faced with this modality.

Faith E. Davies, MD, discusses the dosing of carfilzomib in the treatment of patients with multiple myeloma.

Gareth J. Morgan, MD, PhD, discusses the role of venetoclax in treating patients with multiple myeloma.

Faith E. Davies, MD, discusses the use of venetoclax as a precision medicine approach in patients with relapsed/refractory multiple myeloma.

A cure concept has not yet been established for asymptomatic and untreated patients with high-risk smoldering myeloma, and debate needs to be initiated surrounding how these patients can be treated sustainably while also taking into account their age, comorbidities, fitness, personal preference, and adverse events of the therapeutic agents.

Robb S. Friedman, MD, discusses the mechanism of action of selinexor in multiple myeloma.

Marc J. Braunstein, MD, PhD, discusses transplant eligibility in multiple myeloma.

Ajai Chari, MD, discusses the impact of the COVID-19 outbreak on hospital protocols and the measures that are being taken to reduce the spread of the virus.

Ken Shain, MD, PhD, discusses isatuximab-irfc and its potential to move into different stages of the multiple myeloma paradigm following further clinical investigation.

A biologics license application has been submitted to the FDA for idecabtagene vicleucel (ide-cel; bb2121) for the treatment of adult patients with multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.

Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Kraft Family Chair, senior physician, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses ways to test for minimal residual disease (MRD) in multiple myeloma.

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses ongoing research in multiple myeloma.

Jens Hillengass, MD, discusses available imaging modalities in multiple myeloma.